Stay updated on the progress of our pioneering endeavors.

Recently, GPN01530-2, an innovative FAP-targeted radiopharmaceutical developed by Grand Pharmaceutical Group Limited (00512.HK), was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA), becoming the world’s first FAP-targeted diagnostic RDC for solid tumors to receive FDA Fast Track Designation. The designation is primarily granted to investigational drugs intended to treat serious conditions and with the potential to address unmet medical needs, with the aim of accelerating the review process for high-value drug candidates.

On July 12, the 2026 (43rd) National Medicinal Industry Information Annual Conference was held in Beijing. At the conference, the China National Pharmaceutical Industry Information Center released the 2025 Top 100 Pharmaceutical Industrial Enterprises in China by Main Business Revenue. China Grand Enterprises, Inc. was once again included in the ranking, ranking fourth.

On August 9, Huadong Medicine Co., Ltd. (000963.SZ) announced that KIO015 (trade name: Kytogen® Defend), an injectable carboxymethyl chitosan solution featuring a novel patented ingredient developed by its wholly owned UK subsidiary, Sinclair Pharma Limited, had been granted the EU MDR CE certification, gaining market access in the European Union. The product is indicated for intradermal injection, superficial filling, skin quality improvement, and skin hydration.

Grand Pharma’s subsidiary launched innovative dual‑mechanism nasal spray Ryaltris® in China, filling the clinical gap for allergic rhinitis combination therapies, especially for patients aged 6+. It enriches the firm’s respiratory portfolio and supports standardized, precise treatment while addressing high disease prevalence.

Sinclair has partnered with Harvard Medical School’s Massachusetts General Hospital to introduce the renowned Magic Wand Initiative (MWI) to Asia for the first time. The collaboration is set to inject new momentum into the innovative development of the medical aesthetics industry in the Asia-Pacific region.

From October 17 to 19, 2024, Sinclair once again set sail in the vibrant, artistic city of Barcelona, bringing a wealth of academic enthusiasm to the event. Joined by nearly a thousand global medical aesthetic practitioners, industry leaders, and media representatives, Sinclair co-hosted the World Expert Meeting 2024 (WEM)–the Sinclair Global Medical Aesthetics Summit.